share_log

DexCom | 10-Q: Q3 2024 Earnings Report

DexCom | 10-Q: Q3 2024 Earnings Report

德康医疗 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/25 05:14

Moomoo AI 已提取核心信息

DexCom reported Q3 2024 revenue of $994.2 million, up 2% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 12% to $134.6 million. However, gross profit declined 5% to $593.8 million due to product mix changes and a $24.6 million inventory charge.Operating income fell 26% to $152.0 million as operating expenses increased 6%. International revenue grew 12% to $292.3 million, while U.S. revenue dipped 2% to $701.9 million. The company added approximately 600,000 net users to its worldwide customer base in 2023.DexCom ended Q3 with $2.49 billion in cash and investments. For the full nine months, revenue increased 13% to $2.92 billion and net income jumped 49% to $424.5 million. The company expects continued growth from its CGM systems and new Stelo biosensor for prediabetes and Type 2 diabetes patients.
DexCom reported Q3 2024 revenue of $994.2 million, up 2% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 12% to $134.6 million. However, gross profit declined 5% to $593.8 million due to product mix changes and a $24.6 million inventory charge.Operating income fell 26% to $152.0 million as operating expenses increased 6%. International revenue grew 12% to $292.3 million, while U.S. revenue dipped 2% to $701.9 million. The company added approximately 600,000 net users to its worldwide customer base in 2023.DexCom ended Q3 with $2.49 billion in cash and investments. For the full nine months, revenue increased 13% to $2.92 billion and net income jumped 49% to $424.5 million. The company expects continued growth from its CGM systems and new Stelo biosensor for prediabetes and Type 2 diabetes patients.
德康医疗报告2024年第三季度的营业收入为$99420万，同比增长2%，这得益于一次性传感器的销售量增加。净利润增长了12%，达到了$13460万。然而，由于产品组合变化和$2460万的库存费用，毛利润下降了5%，降至$59380万。营业收入下降了26%，降至$15200万，因营业费用增加了6%。国际营业收入增长了12%，达到$29230万，而美国营业收入下降了2%，降至$70190万。该公司在2023年向其全球客户基础新增了约600,000名用户。德康医疗在第三季度末现金和投资达到了$24.9亿。完整的九个月内，营业收入增长了13%，达到$29.2亿，净利润猛增49%，达到了$42450万。该公司预计其CGM系统和新款Stelo生物传感器在前驱糖尿病和2型糖尿病患者中将持续增长。
德康医疗报告2024年第三季度的营业收入为$99420万，同比增长2%，这得益于一次性传感器的销售量增加。净利润增长了12%，达到了$13460万。然而，由于产品组合变化和$2460万的库存费用，毛利润下降了5%，降至$59380万。营业收入下降了26%，降至$15200万，因营业费用增加了6%。国际营业收入增长了12%，达到$29230万，而美国营业收入下降了2%，降至$70190万。该公司在2023年向其全球客户基础新增了约600,000名用户。德康医疗在第三季度末现金和投资达到了$24.9亿。完整的九个月内，营业收入增长了13%，达到$29.2亿，净利润猛增49%，达到了$42450万。该公司预计其CGM系统和新款Stelo生物传感器在前驱糖尿病和2型糖尿病患者中将持续增长。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间